Tirzepatide(Dual GLP-1 Receptor Agonist) – 10mg
$130.00
- Goals: Metabolic optimization, body recomposition, appetite regulation
- Administration: 2.5–15 mg subcutaneously, once weekly (research settings)
- Cycle Length: 8–24 weeks
- Note: A dual GLP-1 and GIP receptor agonist peptide studied for its effects on weight management and insulin sensitivity
Tirzepatide is a long-acting research peptide designed to activate both GLP-1 and GIP receptors, enhancing insulin response, improving metabolic efficiency, and promoting fat loss while maintaining lean mass in controlled metabolic research applications.
Related products
What is Tirzepatide?
Tirzepatide is a synthetic dual-acting peptide that functions as both a **GLP-1 (Glucagon-Like Peptide-1)** and **GIP (Glucose-Dependent Insulinotropic Polypeptide)** receptor agonist. Originally developed for research into metabolic disorders such as Type 2 diabetes and obesity, Tirzepatide has demonstrated remarkable potential for improving glucose control and promoting significant fat loss. By mimicking natural incretin hormones, it supports enhanced insulin secretion, delayed gastric emptying, and reduced appetite response.
How Does Tirzepatide Work?
Tirzepatide’s mechanism is unique because it activates **two incretin pathways** simultaneously:
- GLP-1 Receptor Activation: Stimulates insulin release, reduces glucagon levels, and slows gastric emptying to stabilize blood glucose.
- GIP Receptor Activation: Enhances insulin sensitivity and complements GLP-1 action for improved metabolic efficiency.
Together, these actions improve glycemic control and support fat reduction while maintaining lean muscle mass, making Tirzepatide a groundbreaking candidate for metabolic and weight-related research.
Chemical Properties
| Chemical Name | Tirzepatide |
| CAS Number | 2023788-19-2 |
| Molecular Formula | C225H348N48O68 |
| Molecular Weight | ≈ 4813.5 g/mol |
| Peptide Class | Dual GLP-1 and GIP receptor agonist |
Potential Benefits of Tirzepatide
- Metabolic Optimization: Enhances glucose metabolism and insulin sensitivity in preclinical studies.
- Body Composition Support: Promotes fat loss while preserving lean muscle mass.
- Appetite Regulation: Reduces hunger response and improves satiety through dual hormone modulation.
- Cardiometabolic Health: Potential benefits include improved lipid profiles and reduced inflammation markers.
Clinical Research & Findings
Clinical studies have shown Tirzepatide’s powerful effect on **weight reduction** and **glycemic control**, outperforming traditional GLP-1 agonists in multiple trials. Its dual receptor activity is considered a major step forward in incretin-based therapies, with research suggesting applications for **obesity, insulin resistance, and cardiovascular risk reduction**. Current findings point to sustained metabolic improvements with continued administration under controlled research conditions.
Dosage & Research Protocols
- Research Dose: 2.5–15 mg weekly (commonly titrated from 2.5 mg upward)
- Administration: Subcutaneous injection (once per week)
- Cycle Length: 8–24 weeks (varies by study design)
Due to its long half-life and sustained receptor engagement, Tirzepatide is typically studied under weekly dosing protocols. Researchers monitor dose-dependent effects on metabolic and hormonal markers across multi-week trials.
FAQs
Is Tirzepatide legal in Canada?
Yes. Tirzepatide is legal for **research use only** in Canada but is not approved for human or veterinary use outside authorized studies.
What are the main research applications of Tirzepatide?
Research focuses on its impact on **obesity, Type 2 diabetes, metabolic health,** and **insulin sensitivity**.
How is Tirzepatide administered?
It is studied via **subcutaneous injection**, typically once weekly, to evaluate metabolic and hormonal responses.
What makes Tirzepatide different from other GLP-1 agonists?
Unlike traditional GLP-1-only peptides (e.g., Semaglutide), Tirzepatide also activates **GIP receptors**, leading to enhanced metabolic outcomes and greater potential fat loss.
Disclaimer
For laboratory use only. Not for human or veterinary use.
This compound is intended strictly for scientific research under controlled laboratory conditions. Researchers are responsible for ensuring ethical and legal compliance with all institutional, local, and federal regulations.
{
“@context”: “https://schema.org
“,
“@type”: “FAQPage”,
“mainEntity”: [
{
“@type”: “Question”,
“name”: “Is Tirzepatide legal in Canada?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Yes. Tirzepatide is legal for research use in Canada but not approved for human or veterinary use.”
}
},
{
“@type”: “Question”,
“name”: “What are the main research applications of Tirzepatide?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Research applications include obesity, metabolic regulation, Type 2 diabetes, and insulin sensitivity.”
}
},
{
“@type”: “Question”,
“name”: “How is Tirzepatide administered?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “It is studied via subcutaneous injection, typically once weekly, depending on the research protocol.”
}
},
{
“@type”: “Question”,
“name”: “What makes Tirzepatide different from other GLP-1 agonists?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Tirzepatide acts as a dual GLP-1 and GIP receptor agonist, enhancing both insulin response and fat loss compared to GLP-1-only peptides.”
}
}
]
}
Be the first to review “Tirzepatide(Dual GLP-1 Receptor Agonist) – 10mg”
You must be logged in to post a review.
SEPTEMBER 29TH, 2025 – IMPORTANT SHIPPING UPDATE
Reviews
There are no reviews yet.